Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00121667 · ClinicalTrials.gov registry record · Phase 3

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
1,462
Enrollment target
20
Study locations

NCT00121667 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by AstraZeneca. The registered enrollment target is 1,462 participants, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00121667, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
1,462 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG Pioglitazone
  • DRUG Saxagliptin + Metformin
  • DRUG Placebo + Metformin

Study Locations (20)

California

  • Local Institution - Encino
  • Local Institution - Fountain Valley
  • Local Institution - Fresno
  • Local Institution - Los Angeles
  • Local Institution - Mission Viejo
  • Local Institution - Northridge
  • Local Institution - Orange
  • Local Institution - Roseville
  • Local Institution - Sacramento
  • Local Institution - Spring Valley
  • Local Institution - Tustin

Alabama

  • Local Institution - Anniston
  • Local Institution - Birmingham
  • Local Institution - Calera
  • Local Institution - Haleyville

Arkansas

  • Local Institution - Jonesboro
  • Local Institution - Little Rock
  • Local Institution - Sherwood

Arizona

  • Local Institution - Mesa
  • Local Institution - Phoenix

Trial Details

FieldValue
Enrollment Target 1,462 participants
Start Date 2005-08
Est. Completion 2010-02
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00121667

The ClinicalTrials.gov registry entry for NCT00121667 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,462 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Pioglitazone is the first listed.

NCT00121667 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00121667 about?

NCT00121667 is a clinical study titled "Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone". The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone

What is the current status of trial NCT00121667?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,462 participants. The study started on 2005-08. Estimated completion is 2010-02.

What conditions does trial NCT00121667 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00121667?

The interventions under investigation include: Pioglitazone (DRUG), Saxagliptin + Metformin (DRUG), Placebo + Metformin (DRUG).

Who is sponsoring clinical trial NCT00121667?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00121667 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.